, Tracking Stock Market Picks
Enter Symbol:
Biomimetic Therapeutics, Inc. (BMTI) [hlAlert]

down 17.69 %

Biomimetic Therapeutics, Inc. (BMTI) rated Outperform with price target $20 by Wedbush

Posted on: Thursday,  Nov 4, 2010  8:25 AM ET by Wedbush

Wedbush rated Outperform Biomimetic Therapeutics, Inc. (NASDAQ: BMTI) on 11/04/2010, when the stock price was $11.53. Since
then, Biomimetic Therapeutics, Inc. has lost 17.69% as of 02/28/2013's recent price of $9.49.
If you would have followed this Wedbush 's recommendation on BMTI, you would have lost 17.69% of your investment in 847 days.

BioMimetic Therapeutics, Inc. (BioMimetic) develops and commercializes products to stimulate the body?s natural tissue regenerative process. The Company?s protein therapeutic-device combination products are used for the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage. The Company?s platform regenerative technology, which incorporates a potent version of one of the body?s natural key stimulators of tissue repair, may offer physicians advanced biological solutions to actively stimulate tissue healing and regeneration. The Company focuses on developing GEM 21S technology to stimulate tissue healing in orthopedic applications (such as distal radius, or wrist, fractures and fusions of the bones in the foot and ankle to eliminate chronic pain from trauma or arthritis), and potentially spine and sports injury applications.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/4/2010 8:25 AM Buy
11.53 20.00
as of 12/31/2010
1 Week up  4.95 %
1 Month up  21.50 %
3 Months up  17.60 %
1 YTD up  17.60 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy